To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.
Patients with newly diagnosed multiple myeloma status post 1st auto-HCT (day 60 - 180 post-transplant).
Disease status (MRD positive or negative), partial response, or better.
Age > 18-year and 75-year. Non-English speaking patients are eligible.
Karnofsky performance status 70 (Appendix A.).
History of progressive disease at any time before starting maintenance.
Patients with smoldering MM (IMWG criteria, Appendix F.).
Patients with plasma cell leukemia.
Patients with non-secretory MM (no measurable disease on electrophoresis and immunofixation). Patients with a measurable disease on PET scan or bone marrow will be eligible.